|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||10.89 - 10.89|
|52-week range||10.89 - 10.89|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial